In a mouse model of type 2 diabetes, semaglutide restored pancreatic beta cell function by activating a specific RNA modification enzyme (METTL14) and reshaping the gut microbiome toward healthier bacterial populations.
METTL14 restoredSemaglutide upregulated this RNA-modifying enzyme in diabetic mice, revealing a previously unknown mechanism for beta cell protection
What the researchers found
Semaglutide treatment (40 μg/kg for 4 weeks) in diabetic mice reversed pancreatic damage, enhanced islet cell proliferation, and restored both alpha- and beta-cell masses to near-normal levels. At the molecular level, semaglutide upregulated the m6A methyltransferase METTL14, which regulated PDX-1 expression in an m6A-dependent manner — a previously unknown mechanism for semaglutide's beta cell protection.
The drug also significantly altered gut microbiota composition, decreasing Firmicutes, Actinobacteriota, and Lactobacillus abundance while increasing Bacteroides and norank_f_Muribaculaceae. Short-chain fatty acid production was also boosted, suggesting a gut-pancreas signaling axis.
Why it matters
Most people know semaglutide as a weight loss and blood sugar drug, but this study reveals it may also protect the insulin-producing cells themselves through a newly identified RNA modification pathway. If these molecular mechanisms translate to humans, it could mean semaglutide does more than manage diabetes symptoms — it might help preserve the beta cells that diabetes gradually destroys.
How the study worked
Researchers used five-week-old male C57BL/6 mice, splitting them into control and high-fat diet groups. After four weeks on a high-fat diet, type 2 diabetes was induced using streptozotocin injections. Diabetic mice then received either no treatment or semaglutide (40 μg/kg) for another four weeks. The team examined pancreatic tissue using immunofluorescence, measured protein levels with Western blot, and assessed gene expression with RT-qPCR. They also studied the mechanism in palmitic acid-stressed beta-TC-6 cells in the lab and analyzed gut bacteria composition.
What this study cannot tell us
This was an animal study using mice, so results may not directly apply to humans. The diabetes model used streptozotocin, which causes more severe beta cell damage than typical human type 2 diabetes. The study period was only four weeks, too short to assess long-term beta cell preservation. The specific contribution of gut microbiome changes versus direct METTL14 effects was not fully disentangled.
How to read the evidence
This is a preclinical animal study using a standard mouse model of type 2 diabetes. While the experimental design included proper controls and multiple analytical methods, the findings have not been validated in humans, limiting their direct clinical applicability.
When this study was published
Published in 2025 in Life Sciences, this is a very recent study exploring cutting-edge molecular mechanisms of a widely prescribed drug.
The bigger picture
GLP-1 receptor agonists like semaglutide are already blockbuster drugs, but scientists are still uncovering exactly how they work at the cellular level. This study adds a new mechanism — m6A RNA modification via METTL14 — to the growing list of semaglutide's biological effects. The gut microbiome connection also supports the emerging idea that metabolic drugs don't just act on one organ but reshape the entire gut-pancreas communication network.
Questions still open
- Does semaglutide regulate METTL14 expression in human pancreatic beta cells the same way it does in mice?
- Could the gut microbiome changes driven by semaglutide independently contribute to beta cell protection?
- Would other GLP-1 receptor agonists like tirzepatide show similar effects on m6A modification pathways?
Common questions
What is METTL14 and why does it matter for diabetes?
Does this study mean semaglutide can cure type 2 diabetes?
Read the original research
Semaglutide alleviates the pancreatic β cell function via the METTL14 signaling and modulating gut microbiota in type 2 diabetes mellitus mice.
Life sciences, 361, 123328
Citation
Luo, Yunfei; Li, Jin-E; Zeng, Haixia; Zhang, Yuying; Yang, Shiqi; Liu, Jianping. (2025). Semaglutide alleviates the pancreatic β cell function via the METTL14 signaling and modulating gut microbiota in type 2 diabetes mellitus mice.. Life sciences, 361, 123328. https://doi.org/10.1016/j.lfs.2024.123328